New Perspectives on Gx Price Inflation: Oral Solids vs InjectablesFebruary 12, 2018
Each month the pharma supply chain research team here at Nephron publishes a unique analysis of brand and generic price trends which differs from other industry measures owing to the fact that it is weighted for sales and is based on pharmacy and distributors generic acquisition cost.
With today’s Nephron Price Auditor Monthly, we have for the first time subdivided the Gx marketplace between oral solids and injectables. We find that the variance in Gx oral solid pricing trends (which account for the majority of wholesaler sourcing program volumes) has been considerably greater than the variability of the broader market. To illustrate this trend and demonstrate our new perspective on generic pricing we have included data for 2014 to 2016 in Fig 1. (Monthly data extending from Jan 2017 to Feb 2018 is available to Nephron research subscribers – for more info email us at firstname.lastname@example.org).